About us
Beyond LGMD Foundation was founded to support and act for children and families affected by the ultra-rare muscle disease Limb-Girdle Muscular Dystrophy.
Our mission is to improve diagnosis, treatment, care, quality of life and future for people living with LGMD Sarcoglycanopathy and related neuromuscular conditions
We pursue this by funding scientific and medical research, supporting development of new therapies and gene therapies, helping patients access clinical trials, and connecting families, researchers, clinicians and care across the globe
Want to know more about our foundation and where we are heading? Read our policy plan 2026–2030.



LGMD Explained
Limb-Girdle Muscular Dystrophy (LGMD) is a group of rare, inherited genetic conditions that cause progressive muscle weakness, primarily affecting the muscles around the hips and shoulders. Symptoms often begin in early childhood or early adulthood and gradually make activities such as walking, climbing stairs, or lifting objects more difficult.
Severity varies by subtype — in the most severe form, sarcoglycanopathies, individuals may lose the ability to walk by their early teens, with the disease later affecting lung and heart function in adulthood.
LGMD is caused by genetic mutations that impair the function of muscle cells, and while there is currently no cure, ongoing research into gene therapies and other innovative treatments offers hope for slowing or stopping disease progression.
Research developments & News
We track and support research into LGMD Sarcoglycanopathy and related subtypes, and share foundation updates as they happen.

Atamyo shares early ATA-200 results for LGMD-R5
March 9, 2026. At the MDA Conference 2026, Atamyo Therapeutics reported 9 month results from the first two patients treated with its ATA-200 gene therapy for LGMD-R5, gamma-sarcoglycanopathy caused by SGCG gene deficiency. Muscle biopsies showed SGCG protein expression above 90 percent, CPK levels dropped significantly, and no serious adverse events were reported across all four treated patients. Read more
FDA proposes faster path for gene therapy development
June 2, 2026. The US FDA issued draft guidance allowing gene therapy developers to use existing scientific and regulatory knowledge, including public data and platform information, to streamline submissions. The agency says the aim is getting safe, effective therapies to patients faster, particularly those with rare and life-threatening diseases. Read more

The Speak Foundation announces 2026 LGMD Scientific Summit
July 27, 2026. The Speak Foundation announced a virtual LGMD Scientific Summit taking place July 31, 2026, bringing together researchers, clinicians, biotechnology innovators, regulators and patient advocates. Sessions cover gene therapy, regenerative medicine, biomarker qualification, natural history studies and patient focused drug development. Read more
Personal Stories

Felix
Felix is 5 years old and lives with LGMD type R5. He throws himself into everything with enthusiasm, even as he notices he’s different when physical challenges arise. The reality is a tough one: every day brings a small loss of strength, right as other children his age are just starting to grow into theirs. There’s no approved treatment yet, but we hold onto hope that medical progress will arrive in time to still change the course of his life. Through it all, Felix stays a bright, energetic boy — comfortable in who he is, and determined to make the most of every day.

Danitia
I am Danitia, 41 years old. Over the years I have lost more and more muscle strength, and physically I have become fully dependent on care. This disease has shaped my life, but it has never defined who I am.
Every day I choose to look at what I can still do — to enjoy the moments that are there, and to live in the here and now with a positive outlook.
I share my story to raise awareness of LGMD, to offer recognition to others, and to contribute to greater understanding, more research and hopefully better treatments for the children who are only now starting out with this diagnosis.
Read Danitia’s diary written for Serieus Request SpierenVoorSpieren
+ More personal stories coming soon
We need your support DONATE
Your gift funds research and support for people living with LGMD Sarcoglycanopathy. Give directly by bank transfer to NL08 INGB 0119 2805 82, t.n.v. St. Beyond LGMD Foundation or use the online payment form
Our Team
Beyond LGMD Foundation is a non-profit foundation run entirely by an unpaid, voluntary board, committed to advancing research, raising awareness, and supporting the LGMD community
L.F. Blankenspoor
Chairman
H.A. Pool – Boeije
Secretary
M.F. Kruitwagen
Treasurer
Contact & details

Partners



